Baird Downgrades Synageva BioPharma (GEVA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Nomura Securities Downgrades Synageva BioPharma (GEVA) to Neutral Amid Takeover
May 7, 2015 8:54 AM EDTNomura Securities downgraded Synageva BioPharma (NASDAQ: GEVA) from Buy to Neutral with a price target of $230.00 following the takeover deal.
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $203.39 yesterday.
... MoreCanaccord Genuity Downgrades Synageva BioPharma (GEVA) to Hold
May 7, 2015 7:00 AM EDTCanaccord Genuity downgraded Synageva BioPharma (NASDAQ: GEVA) from Buy to Hold.
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $203.39 yesterday.
... MoreAlexion Pharma (ALXN) to Acquire Synageva BioPharma (GEVA) for $230/Share
May 6, 2015 6:40 AM EDTAlexion Pharma (NASDAQ: ALXN) and Synageva BioPharma Corp. (Nasdaq: GEVA) announced that they have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015. The acquisition strengthens Alexions global leadership in developing and commercializing transformative therapies for patients with devastating and rare diseases.
The transaction has been unanimously approved by both... More
